Roche’s prasinezumab could slow Parkinson’s motor progression, says GlobalData

While there are currently no marketed disease-modifying therapies (DMTs) for Parkinson’s disease (PD), hope is on the horizon in the shape of prasinezumab (PRX-002), Roche’s (ROG: SIX) monoclonal antibody.

The Swiss pharma giant has presented positive four-year results from a six-year open-label extension of the Phase II PASADENA trial evaluating the efficacy of the drug, which strengthen the hope that it will be able to slow PD motor progression, according to GlobalData, a data and analytics company.

"Recent results from the PASADENA extension greatly raises the anticipation for the conclusion of PADOVA, the ongoing Phase IIb trial"These results were presented at the American Academy of Neurology (AAN) 2024 annual meeting.